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ABSTRACT
Objective: Health-care expenditures are strongly inﬂuenced
by overall illness burden. Appropriate risk adjustment is
required for correct policy analysis. We compared three risk
adjustment methods: the Charlson comorbidity index (CCI),
the chronic disease score (CDS), and the Agency for Health-
care Research and Quality’s comorbidity index (AHRQCI) in
terms of their estimation power in analyzing health-care
expenditures.
Method: Data from the Thomson MarketScan® Research
Databases (Thomson Healthcare, Ann Arbor, MI) were used
to estimate total health-care expenditures of migraine patients
treated by a triptan. Seven distinct multivariate models
were evaluated for model ﬁt (CCI only, CDS only, AHRQCI
only, CCI + CDS, CCI + AHRQCI, CDS + AHRQCI, and
CCI + CDS + AHRQCI). The estimation power of these
indices (alone and in combination) was evaluated using
Bayesian and Akaike information criteria, log-likelihood
scores, and pseudo R2 values.
Results: Conﬁrming results from previous studies, when
comorbidity indices were considered individually the results
were inconclusive. Statistically the best performance was
observed in the model that included all three of the comor-
bidity measures (CCI + CDS + AHRQCI); however, the prac-
tical differences in the estimated values were small.
Conclusion: Low correlation between these comorbidity
indices shows that it is possible to have potential risk factors
that are not captured in the single comorbidity index. Each
comorbidity measure considers different risks, and the col-
linearity of the three measures is not strong enough to pre-
clude using them simultaneously in the same model.
Keywords: comorbidity, health-care costs, regression analy-
sis, risk adjustment.
Introduction
A comorbidity is a condition other than the diagnosis
of interest that may inﬂuence the treatment outcome.
Increasingly, summary measures or comorbidity
indices are being applied in health services research as
proxy measures of overall health status. In fact, it has
become standard in health services research to include
a summary measure of an individual’s comorbid con-
ditions along with other clinical and demographic
characteristics within the multivariate framework.
Being able to capture effectively an individual’s general
health status is particularly important when analyzing
health-care claims data.
Three common comorbidity measures are the
Charlson comorbidity index (CCI), the chronic disease
score (CDS), and the Agency for Healthcare Research
and Quality’s comorbidity index (AHRQCI). CCI con-
tains 19 categories of comorbidity, deﬁned primarily
using ICD-9-CM diagnosis codes (a few procedure
codes are also employed). Each category has an asso-
ciated weight based on the adjusted risk of 1-year
mortality. The overall comorbidity score reﬂects the
cumulative increased likelihood of 1-year mortality—
the higher the score, the more severe the burden of
comorbidity. CDS is a risk-adjusted metric based on
age, sex, and history of dispensed drugs. AHRQCI
contains a comprehensive set of 30 comorbidity mea-
sures, deﬁned using ICD-9-CM diagnosis codes asso-
ciated with increased hospital length of stay, charges,
and mortality.
The predictive validity of individual comorbidity
measures has been examined in detail. Some of these
studies compared different variations for the same
index [1–8], some compared the individual indices in
disease-speciﬁc populations [9–16], some evaluated
validity using different administrative claims data
[17,18], some compared diagnosis-based index scores
with drug-based scores [19–21], and others analyzed
the predictive power in estimating mortality [22–25].
Few studies, however, compare the use of different
measures within the same population when estimating
health-care expenditures [26–28]. Schneeweiss and
Maclure [26] examined the performance of comorbid-
ity scores for use in epidemiologic research, Perkins
et al. [27] evaluated the ability of commonly used
comorbidity measures to predict mortality and health-
care costs over a 1-year period, and Farley et al. [28]
compared several comorbidity indices and count
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measures to predict health-care expenditures. Each of
these studies, however, focused on individual comor-
bidity indices rather than evaluating the effect of using
multiple indices within a single model.
Claims-based comorbidity scores depend both on
the type of clinical conditions included in the develop-
ment of the score and the assigned relative weight, thus
each comorbidity score can proxy the severity of
disease from a different perspective (the distribution of
comorbid conditions in the source population, the
study end point, and the accuracy of the administrative
data were assumed to be constant among the different
index measures when we compared them). Therefore,
combining the index scores in a given model can be
more informative than choosing just one. It has been
suggested that using a single comorbidity index might
be methodologically unsound [1,4,5,29]. Investigators
might consider potential risk factors that are not
captured in the single comorbidity index, but may be
relevant to a patient’s particular condition or proce-
dure. For example, one disadvantage of using medical-
based indices such as CDS is that individuals who do
not receive or ﬁll a prescription will not be detected
[30]. Nevertheless, this individual would be detected
with diagnosis-based scores such as CCI or AHRQCI.
Conversely, diagnosis-based indices assume that differ-
ent diagnoses or differing levels of severity within a
single diagnosis are similar with respect to outcome of
interest [31]. A patient with hypertension and diabetes,
for example, could be considered sicker than a patient
with “only” a stroke. While an important advantage of
administrative data sets is that they offer large, repre-
sentative samples from the population of interest,
applying a single comorbidity index may negate this
beneﬁt.
The goal of this analysis was to compare the per-
formance of CCI, CDS, and AHRQCI, and to examine
the efﬁcacy of their combined use in a single model in
terms of estimating health-care expenditures. Of par-
ticular interest was determining if the concurrent use
of these indices in a single model will predict health-
care expenditures better than using only a single index.
We address these issues by evaluating the health-
care expenditures of patients with a diagnosis of
migraine and a ﬁlled prescription for a triptan as a case
study. Approximately 120 million Americans suffer
from moderate to severe attacks of migraines and the
aggregate cost of providing health care for persons
with migraine is substantial [32]. Triptans are family
of tryptamine drugs currently marketed for the treat-
ment of migraine and cluster headaches. Alternative
treatment choices for migraines differ not only in efﬁ-
cacy and side effects, but also in cost [33]. To estimate
risk adjusted health-care expenditures of migraine
patients with triptan treatment would be the ﬁrst step
to analyze the average treatment effect of triptan use
with respect to other treatment choices. Because
previous studies found that comorbid conditions for
migraine patients inﬂuence health-related expendi-
tures, it is important to control for these factors,
appropriately [34].
Methods
Data Sources
Data used for the analysis were derived from
Thomson’s MarketScan® Commercial Claims and
Encounters Database and MarketScan Medicare
Supplemental and COB Database (Thomson Health-
care, Ann Arbor, MI) from the period of January 1,
2001 to December 31, 2004. In 2004, these databases
represented the health services of approximately 20
million employees, dependents, and retirees in the
United States, with primary or Medicare supplemental
coverage through privately insured fee-for-service,
point-of-service, or capitated health plans.
Sample Selection Criteria
An analytic sample was extracted from the Market-
Scan databases. Individuals who satisﬁed all of the
following criteria were included:
1. at least 12 years of age or older;
2. at least one outpatient diagnosis of migraine (ICD-
9-CM = 346.xx) during the patient identiﬁcation
period (January 1, 2002 through December 31,
2003);
3. at least one ﬁlled prescription for any of the fol-
lowing triptans: sumatriptan (Imitrex®, Imigran®),
rizatriptan (Maxalt®), naratriptan (Amerge®,
Naramig®), zolmitriptan (Zomig®), eletriptan
(Relpax®), almotriptan (Axert®, Almogran®), and
frovatriptan (Frova®, Migard®);
4. at least 6 months of continuous enrollment before
the ﬁrst triptan prescription;
5. at least 12 months of continuous enrollment after
the ﬁrst triptan prescription;
6. eligible for medical and drug beneﬁts during the
18-month study period.
Key Variables and Deﬁnitions
A patient-level analytic ﬁle containing all variables was
constructed from the enrollment and claims data in the
MarketScan databases. In addition to demographic
variables such as age and sex, the analytic ﬁle included
patient location based on US Census categories (north-
east, north central, south, and west) and urban/rural
residency. The ﬁle also contained information about
each patient’s health insurance and his or her provider’s
specialty associated with health-care visits of interest.
The dependent variable—total health
expenditures—was calculated as the sum of all inpa-
tient, outpatient, and outpatient pharmaceutical
expenditures for all medical services. This included all
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services paid for by insurance, as well as out-of-pocket
copayments and deductibles. The analytic ﬁle contains
patients with fee-for-service health plans and those
with partially or fully capitated plans. Data on cost
were not available, however, for the capitated plans.
Therefore, the value of patients’ service utilization
under capitated plan was imputed using average pay-
ments from the MarketScan fee for service by region.
Using standard methodology, which is brieﬂy
described in the following sections, CCI, CDS, and
AHRQCI scores were calculated as measures of overall
health status for each patient in the analytic ﬁle. The
presence or absence of the comorbidities was evaluated
during the preperiod (6 months before index) for
migraine populations with triptan use.
CCI. The most commonly used index in health out-
comes studies is CCI, which assigns a weight ranging
from 1 to 6 according to disease severity for 19 con-
ditions [34]. CCI contents and weighting scheme are
based on Cox proportional hazards modeling [35].
The weights for each condition are summed and a
score is assigned to each patient. The original index
was developed in an inpatient setting, using medical
review to predict the risk of mortality. The index has
since adopted several weights, some of which allow
outpatient diagnoses to contribute to the score [3,29].
Regardless of the version, CCI has practically insigniﬁ-
cant effects in predicting health-care utility and indices
[36,37].
CDS. CDS is an aggregate comorbidity measure based
on current medication use. Von Korff et al. [20]
created CDS to serve as an indicator of an individual’s
morbidity and overall health status. The index was
established under the following guidelines: 1) the score
should increase with the number of chronic diseases
under treatment; 2) the score should increase with the
complexity of the treatment regimen; 3) progressive
and life-threatening diseases should result in higher
scores; and 4) treatment regimens should target dis-
eases and not just symptoms. The ﬁrst three guidelines
are indicative of disease severity while the last ensures
some symptomatic medications are excluded from the
score.
AHRQCI. AHRQCI is based on a comprehensive set
of 30 ICD-9-CM comorbidity ﬂags [38,39]. Diagnosis
codes that represent potential complications are
excluded as indicators of comorbid illness. AHRQCI
uses diagnosis-related groups (DRGs) to differentiate
secondary diagnoses from comorbidities. For example,
if heart failure appeared on a record, it will be counted
as a comorbidity only if the diagnosis does not fall into
any of the cardiac DRGs. The ﬁnal comorbidity scores
can be calculated as the sum of comorbid conditions
present. Current coding for the index is available from
the Agency for Healthcare Research and Quality [38].
The algorithm for the most recently version of the
AHRQCI is presented in the appendix.
Analysis
Total expenditures were estimated as a function of
each unique comorbidity index and as a function of the
combination of the comorbidity indices, adjusting for
an individual’s demographic and utilization character-
istics. These baseline variables included age, sex, geo-
graphic region of residence, and insurance plan type.
Variables noting the year of ﬁrst triptan prescription
and provider specialty were also included. Seven
unique models, each based on the same baseline vari-
ables, were evaluated using the following combina-
tions of comorbidity indices:
• Model 1: baseline variables + CCI;
• Model 2: baseline variables + CDS;
• Model 3: baseline variables + AHRQCI;
• Model 4: baseline variables + CCI + CDS;
• Model 5: baseline variables + CCI + AHRQCI;
• Model 6: baseline variables + CDS + AHRQCI;
• Model 7: baseline variables + CCI + CDS +
AHRQCI.
If there is a strong collinearity between the mea-
sures, it would be redundant to include all of them into
the model because this may increase the variance of
estimated coefﬁcients.
Variance inﬂation factor (VIF) was used to deter-
mine the presence of multicollinearity among the
comorbidity indices. VIF expresses the degree to which
collinearity among the predictors degrades the preci-
sion of an estimate. According to an informal rule of
thumb, there is evidence of multicollinearity if the
largest VIF is greater than 10 and the mean of all VIFs
is considerably larger than 1 [40].
Log-linear and generalized linear models (GLMs)
are two commonly used methods of analyzing health-
care expenditure data. Manning and Mullahy [41]
describe the criteria necessary for choosing between
the two. The Park test, which is applied for family
selection in a GLM [41], indicated that a GLM model
with gamma family was most appropriate for this
analysis.
Bayesian and Akaike information criteria (BIC and
AIC, respectively), log-likelihood scores, and pseudo
R2 values were calculated for all models to determine
the best ﬁt statistically. Pseudo R2 values are the per-
centage reduction of log-likelihood values from the
fully restricted model (model with no covariates) to the
models in question (Model 1 to Model 7).
To compare the prediction performance of the
models, we split the sample randomly into two equal
parts—the training subsample and the test subsample.
Each of the seven models was ﬁtted on the training
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subsample and used to form predictions for all indi-
viduals in the test subsample. Each individual’s pre-
dicted expenditures were compared with that
individual’s actual expenditures. The average squared
prediction error (ASPE) was then computed for each
model.
ASPE E Y Yk k= ( ) −( )∑ 2 ,
where E[.] is the expected value of the term in paren-
theses, and the index k runs through the m individuals
in the test subsample. The ASPE of different models
can be compared directly, with better models produc-
ing smaller ASPE [42,43].
Statistical analysis is done using STATA software,
version 9 (STATA Corp., College Station, TX).
Results
The analytic sample consisted of 47,743 migraine
patients who used a triptan between January 1, 2002
and December 31, 2003. Demographic characteristics
for the sample are provided in Table 1. Sample patients
were on average 40 years of age and disproportion-
ately female (83%). Nearly half resided in the South
and almost three-quarters lived in urban areas.
Twenty-four percent of the sample was insured by a
capitated plan.
Mean scores for CCI, CDS, and AHRQCI were
0.87, 2.27, and 0.45, respectively. Scores ranged from
0 to 28 for CCI, 0 to 17 for CDS, and 0 to 9 for
AHRQCI.
Table 2 presents the results of the multicollinearity
analysis. This analysis indicated no evidence of multi-
collinearity in any of the models according to the crite-
ria mentioned earlier. Furthermore, when considering
the conditional correlations associated with Model 7,
only 10% of the variation in CCI is explained by CDS
and AHRQCI; while 17% of the variation in AHRQCI
is explained by CCI and CDS; and 24% of the variation
inCDS is explained byCCI andAHRQCI. These results
indicate that each index measures things that the other
two do not. Consequently, including all three indices in
the same model would control for unmeasurable varia-
tion which may otherwise occur by excluding them.
Table 3 presents the coefﬁcients, P-values, marginal
effects, and estimated cost values for each of the mul-
tivariate models. Adjusted costs range from $6300 to
$6670, depending on the model. The marginal effect of
a one-point increase in CCI ranges from $646 to
$1075, depending on the model. The corresponding
incremental effects are $556 to $877 and $1500 to
$2724 for CDS and AHRQCI indices, respectively.
In order to choose the best model in terms of pre-
dictability, BIC, AIC, log-likelihood scores, and pseudo
R2 values were calculated for each model. Table 4 pre-
sents the performance of each comorbidity measure
independently and in combination.
When considered individually, results were incon-
clusive. This is consistent with previous literature. In
terms of ASPE, CDS is the most powerful. According
to the pseudo R2, AHRQCI results in greater percent-
age reduction in likelihood value, while BIC indicates
that CCI is the best of the three. When evaluating
the combination of comorbidity indices, Model 4
(CCI + AHRQCI) has the worst performance when
compared to Model 6 (CDS + AHRQCI) and Model 5
(CCI + CDS). Nevertheless, when comparing Model 6
and Model 5, the ASPE criteria clearly indicate that
Model 6 is favored, while pseudo R2 values indicate
that Model 5 is favored. When the data presented in
Table 4 is evaluated in its entirety, the model with the
best ﬁt is the most expanded model—Model 7—which
includes all three comorbidity measures (CCI + CDS +
AHRQCI). Smaller values, indicating better model ﬁt,
were observed for the AIC, BIC, and log-likelihood
scores for Model 7. Hence, minimum ASPE is achieved
Table 1 Sample statistics (N = 47,743)
Variable Mean SD
Total cost 7,495 12,742
Index year 03 0.3072 0.4613
Index year 04 0.0825 0.2752
Age 40.2700 12.3600
Female 0.8358 0.3705
North central 0.2619 0.4400
South 0.4252 0.4944
West 0.2065 0.4048
Urban 0.7788 0.4151
Capitated health plan 0.2464 0.4309
OB/GYN 0.0083 0.0907
Pediatrician 0.0140 0.1174
Pain specialist 0.0004 0.0210
Psychiatrist 0.0183 0.1342
Other physician 0.3360 0.4723
CCI 0.8730 2.0213
AHRQCI 0.4497 0.7903
CDS 2.2622 2.5166
CCI, Charlson comorbidity index; AHRQCI, Agency for Healthcare Research and
Quality’s comorbidity index; CDS, chronic disease score.
Table 2 Analysis of multicollinearity
Model VIF Mean VIF Conditional correlation
Model 4
CCI 1.11
AHRQCI 1.12 1.38 0.29
Model 5
CCI 1.06
CDS 1.10 1.37 0.22
Model 6
AHRQCI 1.18 0.37
CDS 1.20 1.39
Model 7
CCI 1.12 0.10
AHRQCI 1.24 0.17
CDS 1.22 1.38 0.24
VIF, variance inﬂation factor; CCI, Charlson comorbidity index;AHRQCI,Agency for
Healthcare Research and Quality’s comorbidity index; CDS, chronic disease score.
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and, compared with other models, highest percentage
reduction in log-likelihood value is observed by
Model 7.
Discussion
As a forecasting problem, if there is a variable in a
model that has a P-value of 0.0001 in the prediction
equation, every metric (AIC, BIC, etc.) will indicate to
keep that variable. The resulting model will perform
much better in out-of-sample prediction as the ASPE
values demonstrate in Table 4. With a sufﬁciently large
sample, in this case 47,743 observations, it is possible
to have signiﬁcant relationships between the comorbid
measures and the outcome variable because of the
sample size while there is no underlying correlation
that exists. Thus, we performed sensitivity analysis of
the results for randomly chosen subsamples. The
required sample sizes for each model, ranged from
1520 to 1734, and was chosen based on a 5% signiﬁ-
cance level, 90% power, and a speciﬁed effect size
(derived from changes in pseudo R2 values). Conclu-
sions for these models are not different than those
presented for the original study models.
It is possible to have potential risk factors that are
not captured in the single comorbidity index. For
example, AHRQCI covers depression, psychosis, and
drug and alcohol dependence, while neither the CDS
nor the CCI includes these conditions. Moreover,
AHRQCI weights each condition equally where the
CDS and CCI do not. For example, in oncology where
CCI weights are 1 or 2 depending on the cancer type
and CDS weight all cancer drugs as a 3. These differ-
ences are conﬁrmed by the low correlations among the
three commonly measured index scores. Ninety
percent of CCI variation cannot be explained by the
AHRQI and CDS while 83% of AHRQI variation
cannot be explained by CCI and CDS. Similarly, 76%
of CDS variation is not explained by the CCI and
AHRQI.
Low correlation has two important statistical con-
sequences. Health-care expenditures are strongly inﬂu-
enced by overall illness burden and in administrative
data sets; there is a limited set of variables from which
to choose to capture the burden of illness. Because low
correlation suggests that these indices measure differ-
ent aspects of overall illness burden, using a single
index might leave a considerable portion to illness
Table 3 Model parameters
Model Coefﬁcient P-value Marginal effect Estimated cost
Model 1
CCI 0.1613 <0.0001 $1076 $6670
Model 2
AHRQCI 0.4115 <0.0001 $2724 $6620
Model 3
CDS 0.1324 <0.0001 $878 $6629
Model 4
CCI 0.1142 <0.0001 $738
AHRQCI 0.3258 <0.0001 $2104 $6457
Model 5
CCI 0.1270 <0.0001 $815
CDS 0.1114 <0.0001 $715 $6417
Model 6
AHRQCI 0.3035 <0.0001 $1957
CDS 0.0962 <0.0001 $620 $6449
Model 7
CCI 0.1024 <0.0001 $647
AHRQCI 0.2377 <0.0001 $1502
CDS 0.0881 <0.0001 $557 $6320
CCI, Charlson comorbidity index;AHRQCI,Agency for Healthcare Research and Quality’s comorbidity index; CDS, chronic disease score.
Table 4 Comorbidity score performance
Model AIC BIC Log-likelihood Pseudo R2 ASPE
Model 1 (CCI) 19.59916 -466,960 -467,845 0.0124 189769
Model 2 (AHRQCI) 19.59648 -467,088 -467,781 0.0125 188356
Model 3 (CDS) 19.61134 -466,379 -468,136 0.01178 187489
Model 4 (CCI & AHRQCI) 19.54664 -465,458 -466,591 0.0150 182944
Model 5 (CCI & CDS) 19.53419 -465,052 -466,293 0.0156 181369
Model 6 (AHRQCI & CDS) 19.54403 -464,583 -466,528 0.0152 180969
Model 7 (CC,AHRQCI & CDS) 19.50363 -461,502 -465,563 0.0170 147089
AIC,Akaike information criteria; BIC, Bayesian information criteria;ASPE, average squared prediction error; CCI, Charlson comorbidity index;AHRQCI,Agency for Healthcare
Research and Quality’s comorbidity index; CDS, chronic disease score.
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burden to the unmeasurable part of the model. The
resulting estimating coefﬁcients may have omitted vari-
able bias. Omitted variable bias exists when a relevant
covariate is excluded from the model and has serious
statistical consequences. In particular, estimated coef-
ﬁcients and the resulting conclusions for every covari-
ate in the model may not be “trustworthy.”
The second consequence of low correlation is
related to multicollinearity, which refers to any linear
relationship among covariates in a regression model.
Investigators are often reluctant to use more than one
comorbidity index in a single model because of pos-
sible multicollinearity. In the presence of multicol-
linearity, the estimate of one variable’s impact on the
outcome while controlling for others tends to be less
precise than if model covariates were uncorrelated
with one another [44]. When the goal of the model is
a prediction as opposed to the estimation of the effect
of a speciﬁc variable, one should not be concerned
about multicollinearity between variables in the
model. That said, even if we are interested in the
effect of a speciﬁc variable, such as treatment effects,
there is no harm in using these three indices simulta-
neously in a single model because there is no evidence
of multicollinearity. If we exclude these indices for the
sake of avoiding multicollinearity, we run the risk of
omitted variable bias—a much bigger problem than
multicollinearity.
Although the predictive validity of individual
comorbidity measures has been examined in detail,
this study is the ﬁrst to evaluate the effects of using
multiple indices within a single model. We used previ-
ously validated algorithms to create index measures, so
that we can compare our single-measure models with
previously published worked. As in previous studies,
model results were inconclusive.
In general, summing the indicators to a single
value is problematic, because this assumes that the
effect in the original population is the same as in the
study population. For example, it is unlikely that the
effects of comorbid disease on the risk of 1-year mor-
tality found in the original population used to
develop the Charlson index (medical service patients
seen at Cornell Medical Center, New York, NY) are
the same as the effect on total expenditures (as used
in our study of patients with migraines and triptan
treatment). A similar argument can be made with
CDS and AHRQCI. Because the current study has a
relatively large sample size, we tested to see if the
predictive power would be different with individual
indicators rather than the summation scores—
basically seven models with indicator functions
(Table 5). The marginal effects of individual indica-
tors vary widely. The predicted total costs ranged
between $6205 to $6598 and were not signiﬁcantly
different from the predicted costs presented in
Table 3 where summations of indices are used for
risk adjustment. In sum, the results of these
analyses do not change the conclusion of this
study. In particular, there is no evidence of col-
linearity between the three types of indices and
using these three unique indices in a single model
statistically increases the predictive power of our
estimations.
While the changes in AIC, BIC, ASPE, or pseudo R2
values determine the ranking of our models in terms of
predictive power, the actual difference in the predicted
total cost determines what we might call practical sig-
niﬁcance. The differences can be statistically signiﬁcant
without being especially large. A statistically signiﬁ-
cant value being practically or clinically insigniﬁcant
often occurs when working with large samples. There-
fore, a discussion of the practical signiﬁcance along
with statistical signiﬁcance of the estimates is appro-
priate. Results from this health expenditure analysis
suggest that the difference is signiﬁcant statistically,
not practically.
The results of this study should be also be viewed in
light of limitations that are inherent in retrospective
claims data analysis. Correct categorization of insur-
ance database information depends on correct codings
by clinicians and other medical staff. The accuracy of
diagnostic coding cannot be evaluated in a claims-
based study. Patients may also receive treatment that is
not submitted to their health plan for reimbursement
and thus not included in claims data. Data on comor-
bidities were limited to conditions coded on medical
claims within the time frame studied. Finally, the sen-
sitivity analysis applied in this study does not utilize
the full potential of the database. Ideally, one would
perform variable selection procedure and the use of
predictive modeling based on a data mining process
using SAS Enterprise Miner (SAS Institute Inc., Cary,
NC), and then investigate the results via model
comparison.
While more work is warranted to evaluate these
ﬁndings can be supported in other population’s theses
results are, nevertheless, important to pharmacoeco-
nomical researchers for several reasons. First, we ana-
lyzed the use of three common comorbidity indices
(CCI, CDS, and AHRQCI) as methods of risk adjust-
ment in a sample of triptan-using migraine patients
and found that each measures different risks. Second,
we demonstrated that the collinearity of the three mea-
sures was not strong enough to prevent including them
simultaneously in the same model. Finally, we showed
that summing the indicators into a single value ignores
the variations in the effect of each indicator on health-
care expenditures but the estimated risk adjusted
expenditures are not different from those estimated
using summation scores.
Supplementary material for this article can be found at: http://
www.ispor.org/publications/value/ViHsupplementary.asp
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